J Cadranel
Overview
Explore the profile of J Cadranel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
241
Citations
3056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wislez M, Mascaux C, Cadranel J, Thomas Q, Ricordel C, Swalduz A, et al.
Eur J Cancer
. 2025 Feb;
219:115301.
PMID: 39970524
Introduction: Sotorasib has shown efficacy in a phase 3 trial compared to docetaxel among previously treated non-small cell lung cancer (NSCLC) patients with a KRAS G12C mutation. However, its real-world...
2.
Parrot A, Canellas A, Barral M, Gibelin A, Cadranel J
Rev Mal Respir
. 2023 Dec;
41(4):303-316.
PMID: 38155073
In France, even though it occurs only exceptionally in cases of hemopathy, severe hemoptysis in cancer is the leading cause of hemoptysis. Without adequate treatment, in-hospital mortality exceeds 60%, even...
3.
Parrot A, Barral M, Amiot X, Bachmeyer C, Wagner I, Eyries M, et al.
Rev Mal Respir
. 2023 Apr;
40(5):391-405.
PMID: 37062633
Hereditary hemorrhagic telangiectasia, also known as Rendu-Osler - Weber disease, is a rare, autosomal dominant vascular disease, with prevalence of 1/5,000. The condition is characterized by muco-cutaneous telangiectasias, which are...
4.
Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, et al.
Rev Mal Respir
. 2022 Jun;
39(7):e35-e106.
PMID: 35752506
Background: Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. Methods: Under the auspices of the French-speaking Learned Society of Pulmonology...
5.
Cottin V, Bonniaud P, Cadranel J, Jouneau S, Marchand-Adam S, Nunes H, et al.
Rev Mal Respir
. 2022 Mar;
39(3):193-198.
PMID: 35337709
No abstract available.
6.
Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, et al.
Rev Mal Respir
. 2022 Mar;
39(3):275-312.
PMID: 35304014
Background: Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. Methods: Under the auspices of the French-speaking Learned Society of Pulmonology...
7.
Girard N, Galland-Girodet S, Avrillon V, Besse B, Duruisseaux M, Cadranel J, et al.
ESMO Open
. 2022 Mar;
7(2):100418.
PMID: 35227966
Introduction: ROS1-rearranged (ROS1+) non-small-cell lung cancer (NSCLC) is a rare lung cancer with limited treatment options. Phase I-II studies with ROS1-tyrosine kinase inhibitors (TKIs) included small numbers of patients and...
8.
Beaumont A, Doumbia A, Chateau N, Meynard J, Pacanowski J, Valin N, et al.
Int J Tuberc Lung Dis
. 2022 Jan;
26(2):142-149.
PMID: 35086626
Although the burden of TB is lower in France than in low-income countries, patients continue to die from TB in Paris. Our goal was to describe TB-related deaths and to...
9.
Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, et al.
ESMO Open
. 2021 Dec;
7(1):100353.
PMID: 34953398
Background: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC)....
10.
Godet C, Couturaud F, Marchand-Adam S, Pison C, Gagnadoux F, Blanchard E, et al.
Eur Respir J
. 2021 Nov;
59(6).
PMID: 34764182
Background: In allergic bronchopulmonary aspergillosis (ABPA), prolonged nebulised antifungal treatment may be a strategy for maintaining remission. Methods: We performed a randomised, single-blind, clinical trial in 30 centres. Patients with...